Key result
General use of the CardioMEMS sensor for hemodynamic-guided heart failure care led to significant lowering of pulmonary artery pressures, with greater reductions than in the CHAMPION trial.
Why the study?
Does hemodynamic-guided heart failure care using the CardioMEMS sensor reduce pulmonary artery pressures in a general-use, nontrial setting?
Does hemodynamic-guided heart failure care using the CardioMEMS sensor reduce pulmonary artery pressures in a general-use, nontrial setting?
General use of implantable hemodynamic technology in a real-world, nontrial setting leads to significant lowering of pulmonary artery pressures in heart failure patients.
Does not support practice change; extends real-world evidence of greater PA pressure reduction in higher-baseline patients.
The first 2000 general-use patients managed with hemodynamic-guided heart failure care had higher PA pressures at baseline and experienced greater reduction in PA pressure over time compared with the pivotal CHAMPION clinical trial. These data demonstrate that general use of implantable hemodynamic technology in a nontrial setting leads to significant lowering of PA pressures.
No takes yet. Share an insight, caveat, or question.
Heywood et al. (2017) studied this question. General use of the CardioMEMS sensor for hemodynamic-guided heart failure care led to significant lowering of pulmonary artery pressures, with greater reductions than in the CHAMPION trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: